Inhibikase Therapeutics (IKT) News Today $2.97 -0.29 (-8.90%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.94 -0.04 (-1.18%) As of 02/21/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Inhibikase Therapeutics: Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's GrowthFebruary 18, 2025 | finanznachrichten.deInhibikase Therapeutics appoints Mark Iwicki as CEOFebruary 18, 2025 | markets.businessinsider.comInhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s GrowthFebruary 18, 2025 | finance.yahoo.comInhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's GrowthFebruary 18, 2025 | globenewswire.comWhat is HC Wainwright's Estimate for IKT Q1 Earnings?Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) - HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Inhibikase Therapeutics in a research report issued to clients and investors on Wednesday, February 12th. HC Wainwright analyst E. White expects that the company willFebruary 17, 2025 | marketbeat.comHC Wainwright Downgrades Inhibikase Therapeutics (NYSE:IKT) to NeutralFebruary 15, 2025 | americanbankingnews.comHC Wainwright & Co. Downgrades Inhibikase Therapeutics (IKT)February 13, 2025 | msn.comInhibikase Therapeutics downgraded to Neutral from Buy at H.C. WainwrightFebruary 12, 2025 | markets.businessinsider.comInhibikase Therapeutics (NYSE:IKT) Downgraded to Neutral Rating by HC WainwrightHC Wainwright lowered Inhibikase Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday.February 12, 2025 | marketbeat.comInhibikase Halts Parkinson's Drug Development to Focus on PAHJanuary 30, 2025 | msn.comInhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in studyJanuary 29, 2025 | reuters.comInhibikase Therapeutics (NYSE:IKT) Shares Down 2.5% - Should You Sell?Inhibikase Therapeutics (NYSE:IKT) Shares Down 2.5% - Here's WhyJanuary 28, 2025 | marketbeat.comBullish Inhibikase Therapeutics Insiders Loaded Up On US$2.70m Of StockJanuary 21, 2025 | finance.yahoo.comInhibikase Therapeutics (NYSE:IKT) Trading 3.4% Higher - Still a Buy?Inhibikase Therapeutics (NYSE:IKT) Shares Up 3.4% - Time to Buy?December 27, 2024 | marketbeat.comInhibikase Therapeutics (NYSE:IKT) Stock Price Up 7% - What's Next?Inhibikase Therapeutics (NYSE:IKT) Trading 7% Higher - Time to Buy?November 30, 2024 | marketbeat.comInhibikase Therapeutics files to sell 58.31M shares of common stock for holdersNovember 19, 2024 | markets.businessinsider.comInhibikase: Potential To Improve Current Treatment Options For PAH PatientsNovember 19, 2024 | seekingalpha.comInhibikase Therapeutics’ Promising Developments and Financial Backing Justify Buy RatingNovember 15, 2024 | markets.businessinsider.comInhibikase Therapeutics: Strategic Developments and Financial Position Underpin Buy RatingNovember 15, 2024 | markets.businessinsider.comInhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent ActivityNovember 14, 2024 | globenewswire.comJefferies Initiates Coverage of Inhibikase Therapeutics (IKT) with Buy RecommendationNovember 9, 2024 | msn.comInhibikase Therapeutics initiated with a Buy at JefferiesNovember 8, 2024 | markets.businessinsider.comInhibikase Therapeutics initiated with a Buy at JefferiesNovember 8, 2024 | markets.businessinsider.comInhibikase Therapeutics: Promising PAH Market Potential and Strategic Advancements Justify Buy RatingNovember 8, 2024 | markets.businessinsider.comInhibikase Therapeutics: Promising PAH Market Potential and Strategic Advancements Justify Buy RatingNovember 8, 2024 | markets.businessinsider.comInhibikase Therapeutics: Strategic Financial Moves and Promising Pipeline Fuel Buy RatingOctober 24, 2024 | markets.businessinsider.comInhibikase Therapeutics, Inc. (NYSE:IKT) Director Arvind Kush Acquires 145,000 SharesOctober 24, 2024 | insidertrades.comPerceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics IncOctober 22, 2024 | finance.yahoo.comInhibikase Therapeutics Secures Funding and Strengthens LeadershipOctober 22, 2024 | markets.businessinsider.comInhibikase Therapeutics closes up to $275M financing, advances IkT-001ProOctober 22, 2024 | markets.businessinsider.comInhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial HypertensionOctober 21, 2024 | globenewswire.comInhibikase Therapeutics Secures $110M for Drug DevelopmentOctober 12, 2024 | finance.yahoo.comSteven Cohen's Strategic Acquisition of Inhibikase Therapeutics SharesOctober 12, 2024 | finance.yahoo.comInhibikase Therapeutics Unveils PAH and Parkinson’s Drug PipelineOctober 10, 2024 | finance.yahoo.comWhy Inhibikase Therapeutics (IKT) Stock Is Up 50% TodayOctober 10, 2024 | benzinga.comInhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial HypertensionOctober 9, 2024 | globenewswire.comInhibikase Therapeutics, Inc. (NASDAQ:IKT) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | msn.comIKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024August 15, 2024 | markets.businessinsider.comInhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period ActivityAugust 14, 2024 | globenewswire.comWhat Wall Street expects from Inhibikase Therapeutics's earningsAugust 14, 2024 | markets.businessinsider.comInhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024August 7, 2024 | globenewswire.comInhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's DiseaseJune 17, 2024 | globenewswire.comInhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development ProgramsJune 5, 2024 | globenewswire.comInhibikase Therapeutics First Quarter 2024 Earnings: US$0.73 loss per share (vs US$0.98 loss in 1Q 2023)May 21, 2024 | finance.yahoo.comInhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 MillionMay 20, 2024 | globenewswire.comInhibikase Therapeutics, Inc. (NASDAQ:IKT) Q1 2024 Earnings Call TranscriptMay 19, 2024 | msn.comEarnings call: Inhibikase Therapeutics reports on drug trials progressMay 18, 2024 | investing.comIKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q1 2024May 16, 2024 | msn.comInhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period ActivityMay 15, 2024 | globenewswire.comInhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration StatementMay 15, 2024 | globenewswire.com Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address IKT Media Mentions By Week IKT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IKT News Sentiment▼0.640.60▲Average Medical News Sentiment IKT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IKT Articles This Week▼91▲IKT Articles Average Week Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ANAB News KURA News CRMD News ABUS News PHAR News IMTX News ORIC News RAPP News SEPN News PGEN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:IKT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IKT Stock Alerts